Recent Updates — MCUJF

Medicure Inc. reported unaudited financial results for the three and six months ended June 30, 2026. Revenue increased to $15.4 million CAD from $12.2 million CAD in the prior year period, driven by growth in ZYPITAMAG sales through Marley Drug and the newly acquired Gateway and West Olympia pharmacies. However, AGGRASTAT revenue declined significantly due to generic competition. The company posted a net loss of $1.8 million CAD for the six-month period, compared to a $1.5 million loss previously. Cash reserves decreased to $1.8 million CAD from $3.8 million CAD at year-end 2025. Additionally, the filing disclosed executive changes: President and COO Dr. Neil Owens resigned in May 2026 with CEO Dr. Albert Friesen assuming those duties, and CFO Haaris Uddin resigned in July 2026, replaced by interim CFO James Kinley. Medicure Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics and operates retail pharmacies.